Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability

Science Translational Medicine

Volumn 10, Issue 456, 2018, Pages

  King, Andrew J ^a   Siegel, Matthew ^a   He, Ying ^a   Nie, Baoming ^a   Wang, Ji ^a   Koo McCoy, Samantha ^a   Minassian, Natali A ^a   Jafri, Qumber ^a   Pan, Deng ^a   Kohler, Jill ^a   Kumaraswamy, Padmapriya ^a   Kozuka, Kenji ^a   Lewis, Jason G ^a   Dragoli, Dean ^a   Rosenbaum, David P ^a   O'Neill, Debbie ^b   Plain, Allein ^b   Greasley, Peter J ^c   Jönsson Rylander, Ann Cathrine ^c   Karlsson, Daniel ^c   Behrendt, Margareta ^c   Strömstedt, Maria ^c   Ryden Bergsten, Tina ^c   Knöpfel, Thomas ^d   Pastor Arroyo, Eva M ^d   Hernando, Nati ^d   Marks, Joanne ^e   Donowitz, Mark ^f   Wagner, Carsten A ^d   Todd Alexander, R ^g   Caldwell, Jeremy S ^g   more..

^a Ardelyx Inc   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATE; PHOSPHATE TRANSPORTER; PROTEIN NAPI2B; SODIUM PHOSPHATE COTRANSPORTER 2B; SODIUM PROTON EXCHANGE PROTEIN 3; TENAPANOR; UNCLASSIFIED DRUG; ION; ISOQUINOLINE DERIVATIVE; POTASSIUM; PROTON; SODIUM; SULFONAMIDE; TIGHT JUNCTION PROTEIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; ELECTRIC RESISTANCE; END STAGE RENAL DISEASE; FEMALE; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYPERPHOSPHATEMIA; IN VIVO STUDY; INTESTINE EPITHELIUM CELL; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; RAT; TIGHT JUNCTION; ANIMAL; CELL CULTURE; EPITHELIUM; IMPEDANCE; INTESTINE ABSORPTION; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PH; URINE; YOUNG ADULT;

ADULT; AGED; ANIMALS; BASE SEQUENCE; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; ELECTRIC IMPEDANCE; EPITHELIUM; FEMALE; GASTROINTESTINAL TRACT; HEALTHY VOLUNTEERS; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; IONS; ISOQUINOLINES; MALE; MICE; MIDDLE AGED; PHOSPHATES; POTASSIUM; PROTONS; RATS; SODIUM; SODIUM-HYDROGEN EXCHANGER 3; SULFONAMIDES; TIGHT JUNCTION PROTEINS; YOUNG ADULT;

EID: 85052694745     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aam6474     Document Type: Article

References (71)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. Suppl., S1-S130 (2009).
2. J. Walton, T. K. Gray, Absorption of inorganic phosphate in the human small intestine. Clin. Sci. 56, 407-412 (1979).
3. G. R. Davis, J. E. Zerwekh, T. F. Parker, G. J. Krejs, C. Y. Pak, J. S. Fordtran, Absorption of phosphate in the jejunum of patients with chronic renal failure before and after correction of vitamin D deficiency. Gastroenterology 85, 908-916 (1983).
4. J. F. Aloia, J. K. Yeh, Effect of hypophysectomy on intestinal phosphate absorption in rats. Bone 6, 73-77 (1985).
5. K. B. Williams, H. F. DeLuca, Characterization of intestinal phosphate absorption using a novel in vivo method. Am. J. Physiol. Endocrinol. Metab. 292, E1917-E1921 (2007).
6. K. A. Hruska, S. Mathew, R. Lund, P. Qiu, R. Pratt, Hyperphosphatemia of chronic kidney disease. Kidney Int. 74, 148-157 (2008).
7. C. A. Wagner, N. Hernando, I. C. Forster, J. Biber, The SLC34 family of sodium-dependent phosphate transporters. Pflugers Arch. 466, 139-153 (2014).
8. N. D. Toussaint, E. Pedagogos, S.-J. Tan, S. V. Badve, C. M. Hawley, V. Perkovic, G. J. Elder, Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk. Nephrology 17, 433-444 (2012).
9. B. Kestenbaum, J. N. Sampson, K. D. Rudser, D. J. Patterson, S. L. Seliger, B. Young, D. J. Sherrard, D. L. Andress, Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 16, 520-528 (2005).
10. C. P. Kovesdy, S. Ahmadzadeh, J. E. Anderson, K. Kalantar-Zadeh, Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 73, 1296-1302 (2008).
11. H. Eddington, R. Hoefield, S. Sinha, C. Chrysochou, B. Lane, R. N. Foley, J. Hegarty, J. New, D. J. O'Donoghue, R. J. Middleton, P. A. Kalra, Serum phosphate and mortality in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 5, 2251-2257 (2010).
12. S. C. Palmer, A. Hayen, P. Macaskill, F. Pellegrini, J. C. Craig, G. J. Elder, G. F. M. Strippoli, Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-analysis. JAMA 305, 1119-1127 (2011).
13. A. P. McGovern, S. de Lusignan, J. van Vlymen, H. Liyanage, C. R. Tomson, H. Gallagher, M. Rafiq, S. Jones, Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: A large community based cohort study. PLOS ONE 8, e74996 (2013).
14. S. Schwarz, B. K. Trivedi, K. Kalantar-Zadeh, C. P. Kovesdy, Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 1, 825-831 (2006).
15. C. Zhou, F. Wang, J.-W. Wang, L.-X. Zhang, M.-H. Zhao, Mineral and bone disorder and its association with cardiovascular parameters in Chinese patients with chronic kidney disease. Chin. Med. J. 129, 2275-2280 (2016).
16. A. J. Collins, R. N. Foley, D. T. Gilbertson, S.-C. Chen, The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin. J. Am. Soc. Nephrol. 4 (suppl. 1), S5-S11 (2009).
17. T. Isakova, P. Wahl, G. S. Vargas, O. M. Gutiérrez, J. Scialla, H. Xie, D. Appleby, L. Nessel, K. Bellovich, J. Chen, L. Hamm, C. Gadegbeku, E. Horwitz, R. R. Townsend, C. A. M. Anderson, J. P. Lash, C.-Y. Hsu, M. B. Leonard, M. Wolf, Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79, 1370-1378 (2011).
18. T. Isakova, H. Xie, W. Yang, D. Xie, A. H. Anderson, J. Scialla, P. Wahl, O. M. Gutiérrez, S. Steigerwalt, J. He, S. Schwartz, J. Lo, A. Ojo, J. Sondheimer, C.-Y. Hsu, J. Lash, M. Leonard, J. W. Kusek, H. I. Feldman, M. Wolf Chronic Renal Insufficiency Cohort (CRIC) Study Group, Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305, 2432-2439 (2011).
19. J. B. Cannata-Andía, J. L. Fernández-Martín, F. Locatelli, G. London, J. L. Gorriz, J. Floege, M. Ketteler, A. Ferreira, A. Covic, B. Rutkowski, D. Memmos, W. J. Bos, V. Teplan, J. Nagy, C. Tielemans, D. Verbeelen, D. Goldsmith, R. Kramar, P. Y. Martin, R. P. Wüthrich, D. Pavlovic, M. Benedik, J. E. Sánchez, P. Martínez-Camblor, M. Naves-Díaz, J. J. Carrero, C. Zoccali, Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int. 84, 998-1008 (2013).
20. C. Sullivan, S. S. Sayre, J. B. Leon, R. Machekano, T. E. Love, D. Porter, M. Marbury, A. R. Sehgal, Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: A randomized controlled trial. JAMA 301, 629-635 (2009).
21. C. Karamanidou, J. Clatworthy, J. Weinman, R. Horne, A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 9, 2 (2008).
22. Y. W. Chiu, I. Teitelbaum, M. Misra, E. M. de Leon, T. Adzize, R. Mehrotra, Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin. J. Am. Soc. Nephrol. 4, 1089-1096 (2009).
23. Y. Sabbagh, H. Giral, Y. Caldas, M. Levi, S. C. Schiavi, Intestinal phosphate transport. Adv. Chronic Kidney Dis. 18, 85-90 (2011).
24. J. Marks, E. S. Debnam, R. J. Unwin, The role of the gastrointestinal tract in phosphate homeostasis in health and chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 22, 481-487 (2013).
25. J. Amanzadeh, R. F. Reilly Jr., Hypophosphatemia: An evidence-based approach to its clinical consequences and management. Nat. Clin. Pract. Nephrol. 2, 136-148 (2006).
26. N. Hernando, K. Myakala, F. Simona, T. Knopfel, L. Thomas, H. Murer, C. A. Wagner, J. Biber, Intestinal depletion of NaPi-IIb/Slc34a2 in mice: Renal and hormonal adaptation. J. Bone Miner. Res. 30, 1925-1937 (2015).
27. Y. Sabbagh, S. P. O'Brien, W. Song, J. H. Boulanger, A. Stockmann, C. Arbeeny, S. C. Schiavi, Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J. Am. Soc. Nephrol. 20, 2348-2358 (2009).
28. S. C. Schiavi, W. Tang, C. Bracken, S. P. O'Brien, W. Song, J. Boulanger, S. Ryan, L. Phillips, S. Liu, C. Arbeeny, S. Ledbetter, Y. Sabbagh, Npt2b deletion attenuates hyperphosphatemia associated with CKD. J. Am. Soc. Nephrol. 23, 1691-1700 (2012).
29. + /Pi cotransporter. J. Membr. Biol. 212, 177-190 (2006).
30. G. J. Lee, J. Marks, Intestinal phosphate transport: A therapeutic target in chronic kidney disease and beyond? Pediatr. Nephrol. 30, 363-371 (2015).
31. J. Marks, E. S. Debnam, R. J. Unwin, Phosphate homeostasis and the renal-gastrointestinal axis. Am. J. Physiol. Renal Physiol. 299, F285-F296 (2010).
32. D. Günzel, M. Fromm, Claudins and other tight junction proteins. Compr. Physiol. 2, 1819-1852 (2012).
33. D. Günzel, A. S. L. Yu, Claudins and the modulation of tight junction permeability. Physiol. Rev. 93, 525-569 (2013).
34. D. B. Lee, M. W. Walling, D. B. Corry, Phosphate transport across rat jejunum: Influence of sodium, pH, and 1,25-dihydroxyvitamin D3. Am. J. Physiol. 251 (Pt. 1), G90-G95 (1986).
35. + uptake in humans. Sci. Transl. Med. 6, 227ra236 (2014).
36. E. D. Labonté, C. W. Carreras, M. R. Leadbetter, K. Kozuka, J. Kohler, S. Koo-McCoy, L. He, E. Dy, D. Black, Z. Zhong, I. Langsetmo, A. G. Spencer, N. Bell, D. Deshpande, M. Navre, J. G. Lewis, J. W. Jacobs, D. Charmot, Gastrointestinal inhibition of sodium-hydrogen exchanger 3 reduces phosphorus absorption and protects against vascular calcification in CKD. J. Am. Soc. Nephrol. 26, 1138-1149 (2015).
37. J. Marks, S. K. Srai, J. Biber, H. Murer, R. J. Unwin, E. S. Debnam, Intestinal phosphate absorption and the effect of vitamin D: A comparison of rats with mice. Exp. Physiol. 91, 531-537 (2006).
38. K. Kozuka, Y. He, S. Koo-McCoy, P. Kumaraswamy, B. Nie, K. Shaw, P. Chan, M. Leadbetter, L. He, J. G. Lewis, Z. Zhong, D. Charmot, M. Balaa, A. J. King, J. S. Caldwell, M. Siegel, Development and characterization of a human and mouse intestinal epithelial cell monolayer platform. Stem Cell Reports 9, 1976-1990 (2017).
39. R. Agarwal, R. Afzalpurkar, J. S. Fordtran, Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology 107, 548-571 (1994).
40. J. Orlowski, R. A. Kandasamy, G. E. Shull, Molecular cloning of putative members of the Na/H exchanger gene family. cDNA cloning, deduced amino acid sequence, and mRNA tissue expression of the rat Na/H exchanger NHE-1 and two structurally related proteins. J. Biol. Chem. 267, 9331-9339 (1992).
41. S. Hachiya, M. Miura, Y. Imamura, D. Kaga, I. Sato, H. Moritomo, K. Kato, K. Terai, Y. Terada, Tetrahydrobenzothiophene compound. US8729068 B2 (2014).
42. + exchanger in renal microvillus membrane vesicles. Am. J. Physiol. 238, F461-F469 (1980).
43. A. Kato, M. F. Romero, Regulation of electroneutral NaCl absorption by the small intestine. Annu. Rev. Physiol. 73, 261-281 (2011).
44. M. Vastag, W. Neuhofer, W. Nagel, F. X. Beck, Ammonium affects tight junctions and the cytoskeleton in MDCK cells. Pflugers Arch. 449, 384-391 (2005).
45. S. M. Krug, J. D. Schulzke, M. Fromm, Tight junction, selective permeability, and related diseases. Semin. Cell Dev. Biol. 36, 166-176 (2014).
46. + exchanger NHE3. Am. J. Physiol. Cell Physiol. 279, C1918-C1924 (2000).
47. K. F. Farrand, J. B. Copley, J. Heise, M. Fridman, M. S. Keith, L. Poole, Analysis of serum phosphate control and phosphate binder utilization in incident hemodialysis patients. Int. J. Nephrol. Renovasc. Dis. 7, 261-269 (2014).
48. R. B. Fissell, A. Karaboyas, B. A. Bieber, A. Sen, Y. Li, A. A. Lopes, T. Akiba, J. Bommer, J. Ethier, M. Jadoul, R. L. Pisoni, B. M. Robinson, F. Tentori, Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS. Hemodial. Int. 20, 38-49 (2016).
49. S. Wang, T. Alfieri, K. Ramakrishnan, P. Braunhofer, B. A. Newsome, Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis. Nephrol. Dial. Transplant. 29, 2092-2099 (2014).
50. L. R. Gawenis, X. Stien, G. E. Shull, P. J. Schultheis, A. L. Woo, N. M. Walker, L. L. Clarke, Intestinal NaCl transport in NHE2 and NHE3 knockout mice. Am. J. Physiol. Gastrointest. Liver Physiol. 282, G776-G784 (2002).
51. 2+ transport across murine cecum. Am. J. Physiol. Gastrointest. Liver Physiol. 305, G303-G313 (2013).
52. W. Pan, J. Borovac, Z. Spicer, J. G. Hoenderop, R. J. Bindels, G. E. Shull, M. R. Doschak, E. Cordat, R. T. Alexander, The epithelial sodium/proton exchanger, NHE3, is necessary for renal and intestinal calcium (re)absorption. Am. J. Physiol. Renal Physiol. 302, F943-F956 (2012).
53. H. Komaba, M. Fukagawa, Phosphate-A poison for humans? Kidney Int. 90, 753-763 (2016).
54. C. R. Weber, G. H. Liang, Y. Wang, S. Das, L. Shen, A. S. L. Yu, D. J. Nelson, J. R. Turner, Claudin-2-dependent paracellular channels are dynamically gated. eLife 4, e09906 (2015).
55. D. Benner, A. R. Nissenson, D. Van Wyck, Focused clinical campaign improves mineral and bone disorder outcomes. J. Ren. Care 38, 2-8 (2012).
56. F. K. Port, R. L. Pisoni, J. Bommer, F. Locatelli, M. Jadoul, G. Eknoyan, K. Kurokawa, B. J. Canaud, M. P. Finley, E. W. Young, Improving outcomes for dialysis patients in the international Dialysis Outcomes and Practice Patterns Study. Clin. J. Am. Soc. Nephrol. 1, 246-255 (2006).
57. C. G. Joson, S. L. Henry, S. Kim, M. Y. Cheung, P. Parab, A. C. Abcar, S. J. Jacobsen, D. E. Morisky, J. J. Sim, Patient-reported factors associated with poor phosphorus control in a maintenance hemodialysis population. J. Ren. Nutr. 26, 141-148 (2016).
58. G. A. Block, D. P. Rosenbaum, M. Leonsson-Zachrisson, M. Astrand, S. Johansson, M. Knutsson, A. M. Langkilde, G. M. Chertow, Effect of tenapanor on serum phosphate in patients receiving hemodialysis. J. Am. Soc. Nephrol. 28, 1933-1942 (2017).
59. G. A. Block, D. P. Rosenbaum, A. Yan, P. J. Greasley, G. M. Chertow, M. Wolf, The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. Nephrol. Dial. Transplant. (2018).
60. A phase 3 study of tenapanor to treat hyperphosphatemia in ESRD patients on dialysis, https://clinicaltrials.gov/ct2/show/NCT03427125 [accessed 25 July 2018].
61. An 8-week study to evaluate tenapanor in the treatment of hyperphosphatemia in end-stage renal disease patients on hemodialysis (ESRD-HD), https://clinicaltrials.gov/ct2/show/NCT02675998 [accessed 25 July 2018].
62. A phase 1 study to examine the pharmacodynamics of different AZD1722 formulations, https://clinicaltrials.gov/ct2/show/NCT02249936 [accessed 20 December 2016].
63. D. Charmot, J. W. Jacobs, M. R. Leadbetter, M. Navre, C. Carreras, N. Bell, Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders. WO2010078449 A2 (2010).
64. C. W. Carreras, D. Charmot, J. W. Jacobs, E. D. Labonte, J. G. Lewis, NHE3-binding compounds and methods for inhibiting phosphate transport. WO2014169094A2 (2014).
65. J. Borovac, R. S. Barker, J. Rievaj, A. Rasmussen, W. Pan, R. Wevrick, R. T. Alexander, Claudin-4 forms a paracellular barrier, revealing the interdependence of claudin expression in the loose epithelial cell culture model opossum kidney cells. Am. J. Physiol. Cell Physiol. 303, C1278-C1291 (2012).
66. H. Kimizuka, K. Koketsu, Ion transport through cell membrane. J. Theor. Biol. 6, 290-305 (1964).
67. D. Günzel, M. Stuiver, P. J. Kausalya, L. Haisch, S. M. Krug, R. Rosenthal, I. C. Meij, W. Hunziker, M. Fromm, D. Müller, Claudin-10 exists in six alternatively spliced isoforms that exhibit distinct localization and function. J. Cell Sci. 122, 1507-1517 (2009).
68. 2+ on tight junction properties in thick ascending limbs of Henle's loop. Pflugers Arch. 468, 293-303 (2016).
69. B. Stieger, H. Murer, Heterogeneity of brush-border-membrane vesicles from rat small intestine prepared by a precipitation method using Mg/EGTA. Eur. J. Biochem. 135, 95-101 (1983).
70. M. M. Bradford, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254 (1976).
71. + -Pi cotransport by 1,25-dihydroxyvitamin D3 in rabbit duodenal brush-border membrane. Am. J. Physiol. 242, G533-G539 (1982).